Tilorone 125 mg 10 tablets, film-coated

As part of combination therapy:
In children aged 7 to 18 years:

• treatment of influenza and other acute respiratory viral infections (ARVI).
In adults:

• treatment of influenza and other ARVI;

• treatment of herpes infection. Prevention of influenza and other ARVI in adults

Method of application and doses

Tilorone is taken orally, after meals.
For children aged 7 to 18 years:
In uncomplicated forms of influenza and other ARVI - 60 mg once a day on the 1st, 2nd, and 4th days from the start of treatment. The total course dose is 180 mg (3 tablets).
For adults:
For the treatment of influenza and other ARVI - 125 mg per day for the first 2 days of treatment, then 125 mg every 48 hours. The total course is 750 mg (6 tablets). For the prevention of influenza and other ARVI - 125 mg once a week for 6 weeks. The total course is 750 mg (6 tablets).
For the treatment of herpes infection - 125 mg for the first two days, then 125 mg every 48 hours. The total course dose is 1.25-2.5 g (10-20 tablets).
In the treatment of influenza and other ARVI, if symptoms persist for more than 4 days, consult a doctor.

Composition per 1 tablet 125 mg:
Active ingredient: tilorone dihydrochloride (tiloron) - 125.00 mg
Excipients: microcrystalline cellulose (MCC-101) - 148.00 mg, sodium croscarmellose - 12.00 mg, povidone-K25 - 12.00 mg, magnesium stearate - 3.00 mg.
Coating composition: hypromellose - 5.70 mg, titanium dioxide - 2.80 mg, macrogol-4000 - 1.40 mg, dye tropaeolin-0 - 0.10 mg.

Round, biconvex tablets coated with a film, ranging in color from yellow to orange. In a cross-section of the tablet, the film coating and the core of orange color are visible, with inclusions of white or orange of various shades being permissible.

Section: Contraindications

• hypersensitivity to tilorone and other components of the drug.
• pregnancy and lactation
• children under 7 years of age.
• hereditary lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
With caution: in the complex therapy of infectious-allergic and viral encephalomyelitis, the drug is used under medical supervision.
Use during pregnancy and lactation
The drug is contraindicated during pregnancy. If the drug is necessary during lactation, breastfeeding should be discontinued.

Special instructions

The influence of the medicinal product on the ability to drive vehicles and operate mechanisms
The drug does not have a negative effect on the ability to drive vehicles and engage in other potentially dangerous activities, requiring increased attention and quick psychomotor reactions.

Side effects

Possible allergic reactions, dyspeptic phenomena, short-term chills.

Overdose

Cases of drug overdose are not known.

Interaction

Compatible with antibiotics and medications used in the traditional treatment of viral and bacterial diseases. No clinically significant interaction of tilorone with antibiotics and traditional treatments for viral and bacterial diseases has been identified.

Section: Pharmacodynamics

Low-molecular-weight synthetic interferon inducer that stimulates the production of alpha, beta, gamma, and lambda interferons in the body. The main producers of interferon in response to the administration of tilorone are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils, and granulocytes. After oral administration, the peak production of interferon is determined in the sequence of intestine - liver - blood within 4-24 hours. Tilorone has immunomodulatory and antiviral effects. After a single oral administration of tilorone at a dose equivalent to the maximum daily dose for humans, the maximum concentration of lambda interferon in lung tissue was determined after 24 hours, and alpha interferon after 48 hours. The induction of lambda interferon in lung tissue contributes to increased antiviral protection of the respiratory tract during influenza and other respiratory viral infections. It induces the synthesis of interferon in human leukocytes. It stimulates bone marrow stem cells, enhances antibody formation depending on the dose, reduces the degree of immunosuppression, and restores the ratio of T-suppressors to T-helpers. It is effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis viruses, and herpesviruses. The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, resulting in the suppression of virus reproduction.

Pharmacokinetics

After oral administration, it is rapidly absorbed from the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to plasma proteins. The drug is excreted almost unchanged through the intestines (70%) and through the kidneys (9%). The half-life is 48 hours. The drug is not subject to biotransformation and does not accumulate in the body.